Specifically, the enriched KEGG pathways in the low-risk group mainly included allograft rejection, viral protein interaction with cytokine and cytokine receptor, intestinal immune network for IgA production, autoimmune thyroid disease, primary immunodeficiency, antigen processing and presentation, natural killer cell mediated cytotoxicity, graft-versus-host disease, and systemic lupus erythematosus. This evidence concerns the gene CD79A and graft versus host disease.